Want to see GHRS full AI Analyst Report?
Top Page
GH Research
(NASDAQ:GHRS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$20.00
▼(-30.84% Downside)
Action:Reiterated
Date:10/09/26
Overall score reflects a strong capital position (low debt and substantial equity) that supports ongoing development, but is weighed down by persistent pre-revenue losses and negative cash flow, alongside clearly bearish technical momentum with oversold indicators and price below major moving averages.
Positive Factors
Extremely low leverage
GH Research’s negligible debt burden reduces mandatory financing costs and preserves flexibility while clinical programs advance. A largely unlevered balance sheet gives management more room to fund research, absorb development setbacks, and pursue strategic options without immediate leverage constraints.
Negative Factors
No product revenue
The absence of revenue means GH Research has not yet demonstrated commercial product demand or an operating business model that funds itself. Until a candidate is approved and launched, financial performance will remain primarily dependent on capital already available or obtained externally.
Read all positive and negative factors
Positive Factors
Negative Factors
Extremely low leverage
GH Research’s negligible debt burden reduces mandatory financing costs and preserves flexibility while clinical programs advance. A largely unlevered balance sheet gives management more room to fund research, absorb development setbacks, and pursue strategic options without immediate leverage constraints.
Read all positive factors
GH Research (GHRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.45B
Dividend YieldN/A
Average Volume (3M)262.25K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth-33.76%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding68,642,290
10 Day Avg. Volume409,911
30 Day Avg. Volume262,255
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.32K
Enterprise Value/Ebitda-23.11
Forecast
1Y Price Target
$43.38Price Target Upside49.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
GH Research Business Overview & Revenue Model
Company Description
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments,...
GH Research Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -268.00K | -335.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -61.71M | -47.46M | -38.60M | -35.21M | -22.41M | -9.17M |
| Net Income | -62.27M | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M |
Balance Sheet | ||||||
| Total Assets | 372.35M | 288.23M | 188.27M | 226.30M | 254.36M | 279.92M |
| Cash, Cash Equivalents and Short-Term Investments | 362.65M | 280.71M | 149.32M | 161.56M | 165.96M | 276.78M |
| Total Debt | 360.00K | 512.00K | 624.00K | 974.00K | 0.00 | 0.00 |
| Total Liabilities | 12.86M | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M |
| Stockholders Equity | 359.49M | 279.70M | 178.95M | 218.97M | 249.82M | 277.18M |
Cash Flow | ||||||
| Free Cash Flow | -52.53M | -43.67M | -42.33M | -33.44M | -26.27M | -15.39M |
| Operating Cash Flow | -52.39M | -43.55M | -42.28M | -33.34M | -26.20M | -15.28M |
| Investing Cash Flow | 33.99M | 46.17M | 65.14M | -54.10M | -84.69M | -104.00K |
| Financing Cash Flow | 110.71M | 139.65M | -304.00K | -204.00K | 0.00 | 286.45M |
GH Research Technical Analysis
Negative
28.92
Price Trends
27.07
Negative
25.94
Negative
21.18
Negative
Market Momentum
-1.80
Positive
28.96
Positive
12.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GHRS, the sentiment is Negative. The current price of 28.92 is above the 20-day moving average (MA) of 24.69, above the 50-day MA of 27.07, and above the 200-day MA of 21.18, indicating a bearish trend. The MACD of -1.80 indicates Positive momentum. The RSI at 28.96 is Positive, neither overbought nor oversold. The STOCH value of 12.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GHRS.
GH Research Risk Analysis
GH Research disclosed 104 risk factors in its most recent earnings report. GH Research reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GH Research Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.66B | -2.15 | -398.21% | ― | ― | -99.37% | |
53 Neutral | $1.20B | -12.53 | -25.91% | ― | ― | -132.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.45B | -21.11 | -20.86% | ― | ― | -33.76% | |
45 Neutral | $533.15M | -26.59 | -12.56% | ― | ― | -120.28% | |
45 Neutral | $956.33M | -9.83 | -46.46% | ― | ― | -3.04% |
* Healthcare Sector Average
GHRS
GH Research
21.11
8.15
62.89%
CMPS
COMPASS Pathways
12.00
5.71
90.78%
DRUG
Bright Minds Biosciences
54.05
-10.92
-16.81%
ANRO
Alto Neuroscience, Inc.
24.37
18.49
314.46%
LBRX
LB Pharmaceuticals, Inc.
37.22
21.15
131.61%
SPTX
Seaport Therapeutics, Inc.
18.15
-1.69
-8.52%
GH Research Corporate Events
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference
Sep 11, 2026
GH Research PLC, a Dublin-based healthcare company and foreign private issuer on U.S. markets, operates in the biopharmaceutical space with a focus on innovative clinical-stage therapies. The firm regularly engages the global investment community ...
GH Research Files Q2 2026 Results and Updates Corporate Presentation
Aug 6, 2026
On August 6, 2026, GH Research PLC filed a Form 6-K reporting its second quarter 2026 financial results and business updates, and made available an updated corporate presentation as of the same date. The filing also furnished unaudited condensed c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.